A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs AK 002 (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions
  • Sponsors Allakos
  • Most Recent Events

    • 21 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
    • 21 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
    • 26 Sep 2016 Status changed from not yet recruiting to recruiting, as reported in an Allakos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top